

REFERENCES

- Abbruzzese JL, and Lippman SM. (2004). The convergence of cancer prevention and therapy in early-phase clinical drug development. *Cancer Cell*. 6: 321-326.
- Adams, J.M., and Cory, S. (2007). The Bcl-2 apoptotic switch in cancer development and therapy. *Oncogene*. 26: 1324–1337.
- Agarwal ML, Taylor WR, Chernov MV, Chernova OB, and Stark GR. (1998). The p53 network. *J. Biol. Chem*. 273: 1-4.
- Aggarwal BB, Ichikawa H, Garodia P, Weerasinghe P, Sethi G, Bhatt ID, Pandey MK, Shishodia S, and Nair MG. (2006). From traditional Ayurvedic medicine to modern medicine: identification of therapeutic targets for suppression of inflammation and cancer. *Expert Opin Ther Targets*. 10: 87-118.
- Aissat N, Le Tourneau C, Ghouil A, Serova M, Bieche I, Lokiec F, Raymond E, and Faivre S. (2008) Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines. *Cancer Chemother. Pharmacol*. 62: 305-313.
- Ambros V. (2001). microRNAs: tiny regulators with great potential. *Cell*. 107: 823-826.
- Ambros V. (2003). MicroRNA pathways in flies and worms: growth, death, fat, stress and timing. *Cell*. 113: 673-676.
- Ambros V, Bartel B, Bartel DP, Burge CB, Carrington JC, Chen X, Dreyfuss G, Eddy SR, Griffiths-Jones S, Marshall M, Matzke M, Ruvkun G, and Tuschl T. (2003). A uniform system for microRNA annotation. *RNA*. 9:277-279.
- Arellano M, and Moreno S. (1997). Regulation of CDK/cyclin complexes during the cell cycle. *Int. J. Biochem. Cell Biol*. 29: 559-573.
- Ashkenazi A, and Dixit VM. (1998). Death receptors: signaling and modulation. *Science*. 281: 1305–1308.
- Assoian RK, and Zhu X. (1997). Cell anchorage and the cytoskeleton as partners in growth factor dependent cell cycle progression. *Curr Opin Cell Biol*. 9:93-98.
- Avruch J, Zhang XF, and Kyriakis JM. (1994). Raf meets Ras: completing the framework of a signal transduction pathway. *Trends Biochem Sci*. 19:279-83.

- Baehrecke EH. (2003). MiRNAs: micro managers of programmed cell death. *Curr. Biol.* 13: R473-R475
- Balandrin MF, Kinghorn AD, and Farnsworth NR. (1993). Human medicinal agents from plants. *ACS Symposium Series 534, American Chemical Society*, 2-12.
- Bartel DP. (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell.* 116: 281–297.
- Berezikov E, Guryev V, van de Belt J, Wienholds E, Plasterk RH, and Cuppen E. (2005). Phylogenetic shadowing and computational identification of human microRNA genes. *Cell.* 120: 21-24.
- Bergers G, Hanahan D, and Coussens LM. (1998). Angiogenesis and apoptosis are cellular parameters of neoplastic progression in transgenic mouse models of tumorigenesis. *Int. J. Dev. Biol.* 42: 995-1002.
- Berridge MJ, Lipp P, and Bootman MD. (2000). The versatility and universality of calcium signalling. *Nat Rev Mol Cell Biol.* 1: 11-21.
- Bishop JM. (1991). Molecular themes in oncogenesis. *Cell.* 64: 235-248.
- Blower PE, Chung JH, Verducci JS, Lin S, Park JK, Dai Z, Liu CG, Schmittgen TD, Reinhold WC, Croce CM, Weinstein JN, and Sadee W. (2008). MicroRNAs modulate the chemosensitivity in tumor cells. *Mol. Cancer Ther.* 7: 1-9.
- Blower PE, Verducci JS, Lin S, Zhou J, Chung JH, Dai Z, Liu CG, Reinhold W, Lorenzi PL, Kaldjian EP, Croce CM, Weinstein JN, and Sadee W. (2007). MicroRNA expression profiles for NCI-60 cancer cell panel. *Mol. Cancer Ther.* 6:1483-1491
- Bohnsack MT, Czaplinski K, and Gorlich D. (2004). Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. *RNA.* 10: 185-191.
- Bosch TX, and Muñoz N. (2002). The viral etiology of cervical cancer. *Virus Res.* 89: 183-190.
- Boyer SN, Wazer DE, and Band V. (1996). E7 oncoprotein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. *Cancer Research.* 56: 4620-4624.

Branca M, Ciotti M, Santini D, Bonito LD, Benedetto A, Giorgi C, Paba P, Favalli C, Costa S, Agarossi A, Alderisio M, Syrjänen K and HPV-Pathogen ISS Study Group. (2004). Activation of the ERK/MAP kinase pathway in cervical intraepithelial neoplasia is related to grade of the lesion but not to high-risk human papillomavirus, virus clearance, or prognosis in cervical cancer. *Am. J. Clin. Pathol.* 122: 902-911.

Brennecke J, Hipfner DR, Stark A, Russell RB, and Cohen SM. (2003). Bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the pro-apoptotic gene *hid* in *Drosophila*. *Cell.* 113: 25-36.

Brennecke J, Stark A, Russell RB, and Cohen SM. (2005). Principles of microRNA-target recognition. *PLoS Bio.* 3: e85.

Burkill IH. (1996). A dictionary of the economic products of the Malay Peninsular. 2nd Edition, Vol. 1 & 2. Ministry of Agriculture and Cooperatives, Kuala Lumpur, Malaysia.

Cadron I, Van Gorp T, Amant F, Leunen K, Neven P, and Vergote I. (2007). Chemotherapy for recurrent cervical cancer. *Gynecol. Oncol.* 107: S113-118.

Cantley LC, and Neel BG. (1999). New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. *Proc Natl Acad Sci USA.* 96:4240-4245.

Carnero A, and Hannon GJ. (1998). The INK4 family of CDK inhibitors. *Curr. Top. Microbiol. Immunol.* 227: 43-55.

Castellsagué X, Díaz M, de Sanjosé S, Muñoz N, Herrero R, Franceschi S, Peeling RW, Ashley R, Smith JS, Snijders PJ, Meijer CJ, Bosch FX and International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. (2006). Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. *J. Natl. Cancer Inst.* 98: 303-315.

Cai XZ, Hagedorn CH, and Cullen BR. (2004). Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. *RNA.* 10: 1957-1966.

Chen CZ, Li L, Lodish HF, and Bartel DP. (2004). MicroRNAs modulate hematopoietic lineage differentiation. *Science.* 303: 83-86.

Chen JT, Huang CY, Chiang YY, Chen WH, Chiou SH, Chen CY, and Chow KC. (2008). HGF increases cisplatin resistance via down-regulation of AIF in lung cancer cells. *Am. J. Respir. Cell Mol. Biol.* 38: 559-565.

Cittelly DM, Das PM, Spoelstra NS, Edgerton SM, Richer JK, Thor AD, and Jones FE. (2010). Downregulation of miR-342 is associated with tamoxifen resistant breast tumors. *Mol. Cancer*. 9: 317.

Cortés-Funes H. (2002). Antiangiogenesis agents. *Drugs of Today*. 38 (Suppl. A): 11.

Cragg GM, Grothaus PG, and Newman DJ. (2009). Impact of natural products on developing new anti-cancer agents. *Chem. Rev.* 109: 3012-3043.

Creasman WT. (1995) Modifications in the staging for stage I vulvar and stage I cervical cancer. Report of the FIGO committee on gynecologic oncology. *Int. J. Gynecol. Obstet.* 50: 215-216.

Crews CM, Alessandrini A, and Erikson RL. (1992). The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product. *Science*. 258: 478-80.

Da Violante G, Zerrouk N, Richard I, Provot G, Chaumeil JC, Arnaud P. (2002). Evaluation of the cytotoxicity effect of dimethyl sulfoxide (DMSO) on Caco2/TC7 colon tumor cell cultures. *Biol Pharm Bull.* 25:1600-3.

Deacon JM, Evans CD, Yule R, Desai M, Binns W, Taylor C, and Peto J. (2000). Sexual behavior and smoking as determinants of cervical HPV infections and of CIN3 among those infected: a case-control study nested within Manchester cohort. *British Journal of Cancer*. 83: 1565-1572.

de Caestecker MP, Piek E, and Roberts AB. (2000). Role of transforming growth factor-beta signaling in cancer. *J. Natl. Cancer Inst.* 92: 1388-1402.

Denli AM, Tops BBJ, Plasterk RHA, Ketting RF, and Hannon GJ. (2004). Processing of primary microRNAs by the microprocessor complex. *Nature*. 432: 231-235.

Derynck R, Akhurst RJ, and Balmain A. (2001). TGF-beta signaling in tumor suppression and cancer progression. *Nat. Genet.* 29: 117-129.

DeVita VT, Serpick AA, and Carbone PO. (1970). Combination chemotherapy in the treatment of advanced Hodgkin's disease. *Ann Intern Med.* 73:881-895.

DiGiovanni J. (1992). Multistage carcinogenesis in mouse skin. *Pharmacol. Ther.* 63-128.

DiSaia PJ, and Creasman WJ. (2002). Preinvasive disease of the Cervix. In: Clinical gynecologic oncology. 6th Ed, St. Louis C V.: Mosby. p1-34.

Dixit V, and Mak TW. (2002). NF-kappaB signaling. Many roads lead to madrid. *Cell*. 111: 615-619.

Dobashi Y, Shoji M, Jiang SX, Kobayashi M, Kawakubo Y, and Kameya T. (1998). Active cyclin A-CDK2 complex, a possible critical factor for cell proliferation in human primary lung carcinomas. *Am. J. Pathol*. 153: 963-972.

Downward J. (1998). Mechanisms and consequences of activation of protein kinase B/Akt. *Curr Opin Cell Biol*. 10:262-267.

Dyson N, Howley PM, Munger K, and Harlow E. (1989). The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma product. *Science*. 243: 934-937.

Eastman A. (1987). The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. *Pharmacol Ther*. 34: 155-166.

Easton J, Wei T, Lahti JM, and Kidd VJ. (1998). Disruption of the cyclin D/cyclin-dependent kinase/INK4/retinoblastoma protein regulatory pathway in human neuroblastoma. *Cancer Res*. 58: 2624–2632.

Elmore S. (2007). Apoptosis: a review of programmed cell death. *Toxicol Pathol*. 35:495-516.

el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, and Vogelstein B. (1993). WAF1, a potential mediator of p53 tumor suppression. *Cell*. 75: 817-825.

Esquela-Kerscher A, and Slack FJ. (2006). Oncomirs-microRNAs with a role in cancer. *Nature Reviews Cancer*. 4: 259-269.

Evan G, and Littlewood T. (1998). A matter of life and cell death. *Science*. 1281:1317-1322.

Evans T, Rosenthal ET, Youngblom J, Distel D, and Hunt T. (1983). Cyclin: a protein specified by maternal mRNA in sea urchin eggs that is destroyed at each cleavage division. *Cell*. 33:389-396.

- Fearon ER, and Vogelstein B. (1990). A genetic model for colorectal tumorigenesis. *Cell*. 61: 759-767.
- Feng XH, Lin X, and Derynck R. (2000). Smad2, Smad3 and Smad4 cooperate with Sp1 to induce p15(Ink4B) transcription in response to TGF-beta. *EMBO J*. 2000; 19: 5178-5193.
- Ferlay J, Bray F, Pisani P, and Parkin DM. (2004). *GLOBOCAN 2002: Cancer incidence. Mortality and prevalence worldwide*. IARC CancerBase No.5, version 2.0. IARCPress: Lyon.
- FIGO - Fédération of Internationale de Gynécologie et d'Obstétrique. (1971). Classification and staging of malignant tumours in the female pelvis. *Acta Obstet. Gynecol. Scand*. 50: 1-7.
- Firestein GS, and Pisetsky DS. (2002). DNA microarrays: boundless technology or bound by technology? Guidelines for studies using microarray technology. *Arthritis Rheum*. 46: 859-861.
- Florea AM, and Büsselberg D. (2009). Anti-cancer drugs interfere with intracellular calcium signaling. *Neurotoxicology*. 30: 803-810.
- Franco EL, Villa LL, Sobrinho JP, Prado JM, Rousseau MC, Desy M, and Rohan TE. (1999). Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. *Journal of Infectious Disease*. 180: 1415-1423
- Friedman RC, Farh KK, Burge CB, and Bartel DP. (2009). Most mammalian mRNAs are conserved targets of microRNAs. *Genome Res*. 19: 92-105.
- García-Colsas R, Castellsagué X, Bosch X, and González CA. (2005). The role of diet and nutrition in cervical carcinogenesis: a review of recent evidence. *International Journal of Cancer*. 117: 629-637.
- Garrido C, Galluzzi L, Brunet M, Puig PE, Didelot C, and Kroemer G. (2005). Mechanisms of cytochrome c release from mitochondria. *Cell Death Differ*. 13:1423-1433.
- Giaccone G. (2000). Clinical perspectives on platinum resistance. *Drugs*. 59: 9-17.
- Gidding CE, Kellie SJ, Kamps WA, and de Graaf SS. (1999) Vincristine revisited. *Crit. Rev. Oncol. Hematol*. 29: 267-287.

- Girard F, Strausfeld U, Fernandez A, and Lamb NJ. (1991). Cyclin A is required for the onset of DNA replication in mammalian fibroblasts. *Cell*. 67:1169-1179.
- Gilman A, and Philips FS. (1946). The biological actions and therapeutic applications of b-chloroethyl amines and sulfides. *Science*. 103: 409-413.
- Goping I S, Barry M, Liston P, Sawchuk T, Constantinescu G, Michalak KM, and *et al.* (2003). Goping IS, Barry M, Liston P, Sawchuk T, Constantinescu G, Michalak KM, Shostak I, Roberts DL, Hunter AM, Korneluk R, and Bleackley RC. *Immunity*. 18: 355–365.
- Gregory RI, Chendrimada TP, Cooch N, and Shiekhattar R. (2005). Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. *Cell*. 123: 631-640.
- Grishok A, Pasquinelli AE, Conte D, Li N, Parrish S, Ha I, Baillie DL, Fire A, Ruvkun G, and Mello CC. (2001). *Cell*. 106: 23-34.
- Grosshans H, and Slack FJ. (2002). Micro-RNAs: small is plentiful. *J. Cell Biol.* 156: 17-21.
- Guo L, Liu Y, Bai Y, Sun Y, Xiao F, and Guo Y. (2010). Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis. *Eur. J. Cancer*. 46: 1692-1702.
- Hall M, and Peters G. (1996). Genetic alterations of cyclins, cyclin-dependent kinases, and CDK inhibitors in human cancer. *Adv. Cancer Res.* 68: 67-108.
- Hanahan D, and Weinberg RA. (2011). Hallmarks of cancer: the next generation. *Cell*. 144:646-674.
- Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, and Weinberg RA. (1999). Creation of human tumor cells with defined genetic elements. *Nature*. 400: 464-468.
- Harper JW, and Elledge SJ. (1996) Cdk inhibitors in development and cancer. *Curr. Opin. Genet. Dev.* 6: 56-64.
- Harper JW, Elledge SJ, Keyomarsi K, Dynlacht B, Tsai LH, Zhang P, Dobrowolski S, Bai C, Connell-Crowley L, and Swindell E. (1995). Inhibition of cyclin-dependent kinases by p21. *Mol. Biol. Cell*. 6: 387-400.

Harris CC. (1991). Chemical and physical carcinogenesis: Advances and perspectives since 1900s. *Cancer Research*. 51: 5023s-5044s.

Harris CC. (1996). p53 tumor suppressor gene: from the basic research laboratory to the clinic--an abridged historical perspective. *Carcinogenesis*. 17: 1187-1198.

Hatakeyama H, Cheng H, Wirth P, Counsell A, Marcrom SR, Wood CB, Pohlmann PR, Gilbert J, Murphy B, Yarbrough WG, Wheeler DL, Harari PM, Guo Y, Shyr Y, Slebos RJ, and Chung CH. (2010). Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma. *PLoS One*. 5: e12702.

Hayakawa J, Ohmichi M, Kurachi H, Ikegami H, Kimura A, Matsuoka T, Jikihara H, Mercola D, and Murata Y. (1999). Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line. *J. Biol Chem*. 274: 31648-31654.

He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, and Kinzler KW. (1998). Identification of c-MYC as a target of the APC pathway. *Science*. 281: 1509-1512.

Hengst L, and Reed SI. (1998). Inhibitors of the Cip /Kip family. *Curr. Top. Microbiol. Immunol*. 227: 25-41.

Henkels KM, and Turchi JJ. (1999). Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines. *Cancer Res*. 59: 3077-3083.

Hennings H, Glick AB, Greenhaigh DA, Morgan DL, Strickland JE, Tennenbaum T, and Yuspa SH. (1993.) Critical aspects of initiation, promotion and progression in multistage epidermal carcinogenesis. *Proc. Soc. Exp. Biol. Med*. 1: 1-8.

Higashida M, Xu S, Kojima-Yuasa A, Kennedy DO, Murakami A, Ohigashi H, and Matsui-Yuasa I. (2009). 1'-Acetoxychavicol acetate-induced cytotoxicity is accompanied by a rapid and drastic modulation of glutathione metabolism. *Amino Acids*. 36: 107-113.

Hildesheim A, Herrero R, Castle PE, Wacholder S, Bratti MC, Sherman ME, Lorincz AT, Burk RD, Morales J, Rodriguez AC, Helgesen K, Alfaro M, Hutchinson M, Balmaceda I, Greenberg M, and Schiffman M. (2001). HPV co-factors related to the development of cervical cancer: results from a population-based study in Costa Rica. *British Journal of Cancer*. 84: 1219-1226.

Ho GY, Bierman R, Beardsley L, Chang CJ, and Burk RD. (1998). Natural history of cervicovaginal papillomavirus infection in young women. *New England Journal of Medicine*. 338: 423-428.

Holowaty P, Miller AB, Rohan T, and To T. (1999). Natural history of dysplasia of the uterine cervix. *Journal of the National Institute*. 91: 252-258.

Huang DW, Sherman BT, and Lempicki RA. (2009). Systematic and integrative analysis of large gene lists using DAVID Bioinformatics Resources. *Nature Protoc*. 4:44-57.

Ichikawa H, Takada Y, Murakami A, and Aggarwal BB. (2005). Identification of a novel blocker of I κ B α kinase that enhances cellular apoptosis and inhibits cellular invasion through suppression of NF- κ B-regulated gene products. *J. Immunol*. 174: 7383-7392.

Ito K, Nakazato T, and Murakami A. (2004). Induction of apoptosis in human myeloid leukemic cells by 1'-acetoxychavicol acetate through mitochondrial- and Fas-mediated dual mechanism. *Clin. Cancer Res*. 10: 120-130.

Itokawa H, Morita H, Sumitomo T, Totsuka N, and Takeya K. (1987). Antitumor principles from *Alpinia galanga*. *Planta Med*. 53: 32-33.

Janssen AM, and Scheffer JJC. (1985). Acetoxychavicol acetate, an antifungal component of *Alpinia galanga*. *Planta Med*. 6: 507-511.

Kamb A. (1998). Cyclin-dependent kinase inhibitors and human cancer. *Curr. Top. Microbiol. Immunol*. 227: 139-148.

Kanzawa F, Koizumi F, Koh Y, Nakamura T, Tatsumi Y, Fukumoto H, Saijo N, Yoshioka T, and Nishio K. (2001). In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction. *Clin. Cancer Res*. 7: 202-209.

Kaufmann SH, and Hengartner MO. (2001). Programmed cell death: alive and well in the new millennium. *Trends Cell Biol*. 11:526-534.

Kawabata K, Tanaka T, Yamamoto T, Ushida J, Hara A, Murakami A, Koshimizu K, Ohigashi H, Stoner GD, and Mori H. (2000). Suppression of *N*-nitrosomethylbenzylamine-induced rat esophageal tumorigenesis by dietary feeding of 1'-acetoxychavicol acetate. *Jpn. J. Cancer Res*. 91: 148-155.

Kawai Y, Nakao T, Kunimura N, Kohda Y, and Gemba M. (2006). Relationship of intracellular calcium and oxygen radicals to cisplatin-related renal cell injury. *J Pharmacol Sci.* 100: 65–72.

Kelland LR. (1993). New platinum antitumor complexes. *Crit. Rev. Oncol. Hematol.* 15: 191-219.

Kelland LR, Mistry P, Abel G, Loh SY, O'Neill CF, Murrer BA, and Harrap KR. (1992). Mechanism-related circumvention of acquired cis-diamminedichloroplatinumII resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates. *Cancer Research.* 52: 3857-3864.

Kern W, Kohlmann A, Wuchter C, Schnittger S, Schoch C, Mergenthaler S, Ratei R, Ludwig WD, Hiddemann W, and Haferlach T. (2003). Correlation of protein expression and gene expression in acute leukemia. *Cytometry B. Clin. Cytom.* 55: 29-36.

Kerr JF, Wyllie AH, and Currie AR. (1972). Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. *Br. J. Cancer.* 26:239-257.

Keyomarsi K, Conte D, Toyofuku W, and Fox MP. (1995). Deregulation of cyclin E in breast cancer. *Oncogene.* 11: 941-950.

Khalijah A, Azmi MN, In LLA, Ahmad NA, Halijah I, and Hasima NN. (2010). The apoptotic effects of 1'S-1'-acetoxychavicol acetate from *Alpinia conchigera* on human cancer cells. *Molecules.* 15: 8048-8059.

Kim JH, Kang MJ, Park CU, Kwak HJ, Hwang Y, and Koh GY. (1999). Amplified CDK2 and cdc2 activities in primary colorectal carcinoma. *Cancer.* 85: 546-553.

Kim PJ, Plescia J, Clevers H, Fearon ER, and Altieri DC. (2010). Survivin and molecular pathogenesis of colorectal cancer. *Lancet.* 362: 205-219.

King RW, Jackson PK, and Kirschner MW. (1994). Mitosis in transition. *Cell.* 79: 563-571.

Kischke FC, Hellbardt S, Behrmann I, Germer M, Pawlita M, Krammer PH, and Peter ME. (1995). Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. *Embo J.* 14: 5579–5588.

Klaes R, Woerner SM, Ridder R, Wentzensen N, Duerst M, Schneider A, Lotz B, Melsheimer P, and von Knebel Doeberitz M. (1999) Detection of high-risk cervical intraepithelial neoplasia and cervical cancer by amplification of transcripts derived from integrated papillomavirus oncogenes. *Cancer Research*. 59: 6132-6136.

Knudson AG. (1986). Genetics of human cancers. *Annual Review of Genetics*. 20: 231-251.

Ko LJ, and Prives C. (1996). p53: puzzle and paradigm. *Genes Dev*. 10: 1054-1072.

Kondo A, Ohigashi H, Murakami A, Suratwadee J, and Koshimizu K. (1993). 1'-acetoxychavicol acetate as a potent inhibitor of tumor promoter-induced Epstein-Bar virus activation from *Languas galanga*, a traditional Thai condiment. *Biosci. Biotechnol. Biochem*. 57: 1344-1345.

Kress JW, Liu AZ, Newman M, and Li QJ. (2005). The molecular phylogeny of *Alpinia* (Zingiberaceae): a complex and polyphyletic genus of gingers. *American Journal of Botany*. 92:167-178.

Kubota K, Ueda Y, Yasuda M, and Masuda M. (2001). Occurrence and antioxidative activity of 1'-acetoxychavicol acetate and its related compounds in the rhizomes of *Alpinia galanga* during cooking. *Spec. Publ. – R. Soc. Chem*. 274: 601-607.

Lagos-Quitana M, Rauhut R, Lendeckel W, and Tuschl T. (2001). Identification of novel genes coding for small expressed RNAs. *Science*. 294: 853-858.

Lapointe J, Lachance Y, Labrie Y, and Labrie C. (1996). A p18 mutant defective in CDK6 binding in human breast cancer cells. *Cancer Res*. 56: 4586–4589.

Leach FS, Elledge SJ, Sherr CJ, Willson JK, Markowitz S, Kinzler KW, and Vogelstein B. (1993). Amplification of cyclin genes in colorectal carcinomas. *Cancer Res*. 53: 1986-1989.

Lee MH, Reynisdottir I, and Massague J. (1995). Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. *Genes Dev*. 9: 639-649.

Lee S, Choi EJ, Jin C, and Kim DH. (2005). Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. *Gynecol. Oncol*. 97: 26-34.

Lee Y, Kim M, Han J, Yeom K, Lee S, Baek SH, and Kim VN. (2004). MicroRNA genes are transcribed by RNA Polymerase II. *EMBO J*. 23: 4051-4060.

Lewis BP, Burge CB, and Bartel BP. (2005). Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. *Cell*. 120:15-20

Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, Bartel DP, Linsley PS, and Johnson JM. (2005). Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. *Nature*. 433: 767-773.

Lim LP, Lau NC, Weinstein EG, Abdelhakim A, Yekta S, Rhoades MW, Burge CB, and Bartel DP. (2003). The microRNAs of *Caenorhabditis elegans*. *Genes Dev*. 17: 991-1008.

Locksley RM, Killeen N, and Lenardo MJ. (2001). The TNF and TNF receptor superfamilies: integrating mammalian biology. *Cell*. 104: 487–501.

Longley DB, and Johnston PG. (2005). Molecular mechanisms of drug resistance. *J Pathol*. 205: 275-292.

Lowe SW, Cepero E, and Evan G. (2004). Intrinsic tumour suppression. *Nature*. 432: 307-315.

Lytle JR, Yario TA, and Steitz JA. (2007). Target mRNAs are repressed efficiently by microRNA-binding sites in the 5' UTR as in 3' UTR. *Proc. Natl. Acad. Sci. USA*. 104: 9667-9672.

Mehendale S, Aung H, Wang A, Yin JJ, Wang CZ, Xie JT, and Yuan CS. (2005). American ginseng berry extract and ginsenoside reattenuate cisplatin-induced kaolin intake in rats. *Cancer Chemother. Pharmacol*. 56: 63-69.

Marshall CJ. (1991). Tumor suppressor genes. *Cell*. 64: 313-326.

Martinvalet D, Zhu P, and Lieberman J. (2005). Granzyme A induces caspase independent mitochondrial damage, a required first step for apoptosis. *Immunity*. 22: 355–730.

Massagué J. (1998). TGF-beta signal transduction. *Annu. Rev. Biochem*. 67: 753-791.

Matsuda H, Morikawa T, Managi H, and Yoshikawa M. (2003). Antiallergic principles from *Alpinia galanga*: structural requirements of phenylpropanoids for inhibition of degranulation and release of TNF-alpha and IL-4 in RBL-2H3 cells. *Bioorg. Med. Chem. Lett*. 13: 3197-3202.

Matsuda H, Morikawa T, Managi H, and Yoshikawa M. (2003). Antiallergic principles from *Alpinia galanga*: structural requirements of phenylpropanoids for inhibition of degranulation and release of TNF-alpha and IL-4 in RBL-2H3 cells. *Bioorg. Med. Chem. Lett.* 13: 3197-3202.

Meng F, Henson R, Wehbe-Janek H, Ghoshai K, Jacob ST, and Patel T. (2007). MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. *Gastroenterology.* 133: 647-658.

Michael MZ, O' Connor SM, van Holst Pellekaan NG, Young GP, and James RJ. (2003). Reduced accumulation of specific mircoRNAs in colorectal neoplasia. *Mol. Cancer Res.* 1: 882-891.

Mitsui S, Kobayashi S, Nagahori S, and Ogiso A. (1985). Constituents from seeds of *Alpinia galanga* Wild. and their anti-ulcer activities. *Chem. Pharm. Bull.* 24: 2377-2382.

Miyauchi M, Nishikawa A, Furukawa F, Nakamura H, Son HY, Murakami A, Koshimizu K, Ohigashi H, and Hirose M. (2000). Inhibitory effects of 1'-acetoxychavicol acetate on *N*-nitrosobis(2-oxopropyl)-amine-induced initiation of cholangiocarcinogenesis in Syrian hamsters. *Jpn. J. Cancer Res.* 91: 477-481.

Moffatt J, Hashimoto M, Kojima A, Kennedy DO, Murakami A, Koshimizu K, Ohigashi H, and Matsui-Yuasa I. (2000). Apoptosis induced by 1'-acetoxychavicol acetate in Ehrlich ascites tumor cells is associated with modulation of polyamine metabolism and caspase-3 activation. *Carcinogenesis.* 21: 2151-2157.

Murakami A, Ohura S, Nakamura Y, Koshimizu K, and Ohigashi H. (1996). 1'-acetoxychavicol acetate, a superoxide anion generation inhibitor, potently inhibits tumor promotion by 12-*O*-tetradecanolyphorbol-13-acetate in ICR mouse skin. *Oncology.* 53: 386-391.

Nakamura Y, Murakami A, Ohto Y, Torikai K, Tanaka T, and Ohigashi H. (1998). Suppression of tumor promoter-induced oxidative stress and inflammatory responses in mouse skin by superoxide generation inhibitor 1'-acetoxychavicol acetate. *Cancer Res.* 58: 4832-4839.

Nasiell K, Roger V, and Nasiell M. (1986). Behaviour of mild cervical dysplasia during long-term follow-up. *Obstet. Gynecol.* 67: 665-669.

National Cancer Institute (2010a) [Assessed on October 2, 2010]. Available at <http://www.cancer.gov/cancertopics/what-is-cancer>

National Cancer Institute (2010b) [Assessed on October 2, 2010]. Available at <http://www.cancer.gov/cancerinfo/types/cervical>

National Cancer Institute (2010c) [Assessed on October 2, 2010]. Available at <http://www.cancer.gov/cancertopics/chemotherapy-and-you/page2>

Newman DJ, Cragg GM, and Snader KM. (2003). Natural products as sources of new drugs over a period 1981-2002. *J. Nat. Prod.* 66: 1022-1037.

Noble RL. (1990). The discovery of the vinca alkaloids – chemotherapeutic agents against cancer. *Biochem Cell Biol.* 68: 1344-1351.

Noro T, Sekiya T, Katoh M, Oda Y, Miyase T, Kuroyanagi M, Ueno A, and Fukushima S. (1988). Inhibitors of xanthine oxidase from *Alpinia galanga*. *Chem. Pharm. Bull.* 36: 244-248.

Norton L, and Simon R. (1986). The Norton-Simon hypothesis revisited. *Cancer Treat Rep.* 70: 163–169.

Nowell PC. (1976). The clonal evolution of tumor cell populations. *Science.* 194: 23-28.

Ohnishi M, Tanaka T, Makita H, Kawamori T, Mori H, Satoh K, Hara A, Murakami A, Ohigashi H, and Koshimizu K. (1996). Chemopreventive effect of a xanthine oxidase inhibitor, 1'-acetoxychavicol acetate, on rat oral carcinogenesis. *Jpn. J. Cancer Res.* 87: 349-356.

Ohtsubo M, Theodoras AM, Schumacher J, Roberts JM, and Pagano M. (1995). Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. *Mol Cell Biol.* 15:2612-2624.

Okouneva T, Hill BT, Wilson L, and Jordan MA. (2003). The effects of vinflunine, vinorelbine, and vinblastine on centromere dynamics. *Mol. Cancer. Ther.* 2:427-436.

Olsen PH, and Ambros V. (1999). The lin-4 regulatory RNA controls development timing in *Caenorhabditis elegans* by blocking LIN-14 protein synthesis after the initiation of translation. *Dev. Biol.* 216: 671-680.

Ostör AG. (1993). Natural history of cervical intraepithelial neoplasia: a critical review. *Int. J. Gynaec. Pathol.* 12: 186-192.

Ozturk OH, Bozcuk H, Burgucu D, Ekinci D, Ozdogan M, Akca S, and Yildiz M. (2007). Cisplatin cytotoxicity is enhanced with zoledronic acid in A549 lung cancer cell line: Preliminary results of an in vitro study. *Cell Biol. Int.* 31: 1069-1071.

Page R, and Takimoto C. (2004). Cancer management: a multidisciplinary approach: medical, surgical, and radiation oncology. In *Principles of chemotherapy*. 8th edition. Edited by: Pazdur R. New York: PRP; 21-38.

Pan B, Yao KS, Monia BP, Dean NM, McKay RA, Hamilton TC, and O'Dwyer PJ. (2002). Reversal of cisplatin resistance in human ovarian cancer cell lines by a c-jun antisense oligodeoxynucleotide (ISIS 10582): evidence for the role of transcription factor overexpression in determining resistant phenotype. *Biochem. Pharmacol.* 63: 1699-1707.

Pardee AB. (1974.) A restriction point for control of normal animal cell proliferation. *Proc. Natl Acad. Sci. USA.* 71: 1286-1290.

Parkin, DM, Bray F, Ferlay J, and Pisani P. (2001). Estimating the world cancer burden: Globocan 2000. *Int. J. Cancer.* 94: 153-156.

Pattillo RA, Hussa RO, Story MT, Ruckert AC, Shalaby MR, and Mattingly RF. (1977). Tumor antigen and human chorionic gonadotropin in CaSki cells: a new epidermoid cervical cancer cell line. *Science.* 196: 1456-1458.

Persons DL, Yazlovitskaya EM, Cui W, and Pelling JC. (1995). Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin. *Clin Cancer Res.* 5: 1007-1014.

Philipp-Staheli J, Payne SR, and Kemp CJ. (2001). p27(Kip1): regulation and function of a haploinsufficient tumor suppressor and its misregulation in cancer. *Exp Cell Res.* 264:148-168.

Pines J. (1991). Cyclins: wheels within wheels. *Cell Growth Differ.* 2:305-310.

Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P, Huang A, Donahue CJ, Sherwood SW, Baldwin DT, Godowski PJ, Wood WI, Gurney AL, Hillan KJ, Cohen RL, Goddard AD, Botstein D, and Ashkenazi A. (1998). Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. *Nature.* 396: 699-703.

Polyak K, Lee MH, Erdjument BH, Koff A, Roberts JM, Tempst P, and Massague J. (1994). Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. *Cell*. 78: 59-66.

Polyak K, Xia Y, Zweier JL, Kinzler KW, and Vogelstein B. (1997). A model for p53-induced apoptosis. *Nature*. 389: 300-305.

Rao TP, and Kühl M. (2010). An updated overview on Wnt signaling pathways: a prelude for more. *Circ Res*. 106: 1798-1806.

Reynisdottir I, Polyak K, Iavarone, and Massague J. (1995.) Kip/cip and INK4 CDK inhibitors co-operate to induce cell cycle arrest in response to TGF-beta. *Genes Dev*. 9: 1831-1841.

Richart RM. (1990). A modified terminology for cervical intraepithelial neoplasia. *Obstet Gynecol*. 75: 131-133.

Richon VM, Schulte N, and Eastman A. (1987). Multiple mechanisms of resistance to cis-diamminedichloroplatinum^{II} in murine leukemia L1210 cells. *Cancer Research*. 47: 388-393.

Robinson MJ, and Cobb MH. (1997). Mitogen-activated protein kinase pathways. *Curr. Opin. Cell Biol*. 1997; 9: 180-186.

Sanchez Y, Wong C, Thoma RS, Richman R, Wu Z, Piwnica WH, and Elledge SJ. (1997). Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. *Science*. 277: 1497-1501.

Schadendorf D, Worm M, Algermissen B, Kohlmus CM, and Czarnetzki BM. (1994). Chemosensitivity testing of human melanoma: a retrospective analysis of clinical response and in vitro drug sensitivity. *Cancer*. 73: 103-108

Scheffner M, Werness BA, Huibregtse JM, Levine AJ, and Howley PM. (1990). The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes degradation of p53. *Cell*. 63: 1129-1136.

Schiffman M, and Kjaer SK. (2003). Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. *J. Natl. Cancer Inst. Monogr*. 31:14-19.

Selby P. (1984). Acquired resistance to cancer chemotherapy. *Nature*. 288: 1252-1253.

Shepherd JH. (1996) Cervical and vulvar cancer: changes in FIGO definitions of staging. *Br. J. Obstet. Gynaecol.* 103: 405-406.

Sherr CJ. (1994). G1 phase progression: cycling on cue. *Cell.* 79:551-555.

Sherr CJ, and Roberts JM. (1995). Inhibitors of mammalian G1 cyclin-dependent kinases. *Genes Dev.* 9: 1149-1163.

Shi Y, Zou M, Farid NR, and al-Sedairy ST. (1996). Evidence of gene deletion of p21 (WAF1/CIP1), a cyclin-dependent protein kinase inhibitor, in thyroid carcinomas. *Br. J. Cancer.* 74: 1336-1341.

Siddik ZH. (2003). Cisplatin: mode of cytotoxic action and molecular basis of resistance. *Oncogene.* 22: 7265-7279.

Slingerland J, and Pagano M. (2000). Regulation of the cdk inhibitor p27 and its deregulation in cancer. *J. Cell Physiol.* 183:10-17.

Smith JS, Herrero R, Bosetti C, Muñoz N, Bosch FX, Eluf-Neto J, Castellsagué X, Meijer CJ, Van den Brule AJ, Franceschi S, Ashley R and International Agency for Research on Cancer (IARC) Multicentric Cervical Cancer Study Group. (2002a). Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. *Journal of the National Cancer Institute.* 94: 1604-1613.

Smith JS, Muñoz N, Herrero R, Eluf-Neto J, Ngelangel C, Franceschi S, Bosch FX, Walboomers JM, and Peeling RW. (2002b). Evidence for Chlamydia trachomatis as a human papillomavirus cofactor in the etiology of invasive cervical cancer in Brazil and the Philippines. *Journal of Infectious Disease.* 185: 324-331.

Solomon LA, Ali S, Banerjee S, Munkarah AR, Morris RT, and Sarkar FH. (2008). Sensitization of ovarian cancer cells to cisplatin by genistein: The role of NF-kappaB. *J. Ovarian Res.* 1: 9.

Song X, Liu X, Chi W, Liu Y, Wei L, Wang X, and Yu J. (2006). Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1 α gene. *Cancer Chemother. Pharmacol.* 58: 776-784.

Splettstoesser F, Florea AM, and Büsselberg D. (2007). IP3-receptor-antagonist 2-APB attenuates cisplatin induced Ca²⁺-influx in HeLa-S3 cells and prevents activation of calpain. *Br J Pharmacol.* 151: 1176–1186.

Sporn MB. (1996). The war on cancer. *Lancet*. 347. 1377-1381.

Steel GG, and Peckham MJ. (1979). Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. *Int J Radiat Oncol Biol Phys* 5: 85–91.

Szakas G, Paterson JK, Booth-Genthe C, and Gottesman MM. (2006). Targeting multidrug resistance in cancer. *Nat Rev. Drug Discov*. 5: 219-234.

Tanaka T, Makita H, Kawamori T, Kawabata K, Mori H, Murakami A, Satoh K, Hara A, Ohigashi H, and Koshimizu K. (1997). A xanthine oxidase inhibitor 1'-acetocychavicol acetate inhibits azoxymethane-induced colonic aberrant crypt foci in rats. *Carcinogenesis*. 18: 1113-1118.

Tanzer A, and Stadler PF. (2004). Molecular evolution of microRNA cluster. *J. Mol. Biol*. 339: 327-335.

Tao X, Hu W, Ramirez PT, and Kavanagh JJ. (2008). Chemotherapy for recurrent and metastatic cervical cancer. *Gynecol. Oncol*. 110: S67-71.

Taylor WR, and Stark GR. (2001). Regulation of the G2/M transition by p53. *Oncogene*. 20: 1803-1815.

Trapani JA, and Smyth MJ. (2002). Functional significance of the perforin/granzyme cell death pathway. *Nat Rev Immunol*. 2: 735–747.

Teicher BA, Herman TS, Holden SA, Wang YY, Pfeffer MR, Crawford JW, and Frei E 3rd. (1990) Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. *Science*. 247: 1457-1461.

Tetsu O, and McCormick F. (1999). Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. *Nature*. 398: 422-426.

Twiddy D, Cohen GM, Macfarlane M, and Cain K. (2006). Caspase-7 is directly activated by the approximately 700-kDa apoptosome complex and is released as a stable XIAP-caspase-7 approximately 200-kDa complex. *J. Biol. Chem*. 281: 3876-3888.

U.S. Food and Drug Administration. (June 14, 2006). FDA approves topotecan hydrochloride (hycamtin) in combination with cisplatin for the treatment of Stage IVB recurrent or persistent carcinoma of the cervix. [Assessed on October 2, 2010]. Available at <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm095638.htm>

U.S. Food and Drug Administration. (July 14, 2006). FDA approves gemcitabine (Gemzar, Eli Lilly and Company). [Assessed on October 2, 2010]. Available at <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm095615.htm>

U.S. Food and Drug Administration. (January 29, 2010). Tykerb. [Assessed on October 2, 2010]. Available at <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm203522.htm>

Vasudevan S, Tong Y, and Steintz JA. (2007). Switching from repression to activation: microRNAs can up-regulate translation. *Science*. 318: 1931-1934.

Vaux DL, Cory S, and Adams JM. (1988). Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. *Nature*. 335: 440-442.

Venkatraman M, Anto RJ, Nair A, Varghese M, and Karunakaran D. (2005). Biological and chemical inhibitors of NF-kappaB sensitize SiHa cells to cisplatin-induced apoptosis. *Mol. Carcinog*. 44: 51-59.

Vermeulen K, Van Bockstaele DR, and Berneman ZN. (2003). The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. *Cell Prolif*. 36:131-149.

Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, and Muñoz N. (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. *J. Pathol*. 189: 12-19.

Walker DH, and Maller JL. (1991). Role for cyclin A in the dependence of mitosis on completion of DNA replication. *Nature*. 354:314-317.

Wang CZ, Fishbein A, Aung HH, Mehendale SR, Chang WT, Xie JT, Li J, and Yuan CS. (2005). Polyphenol contents in grape-seed extracts correlate with antipic effects in cisplatin-treated rats. *J. Altern. Complement Med*. 11: 1059-1065.

Wang Q, Zhong M, Liu W, Li J, Huang J, and Zheng L. (2011). Alterations of microRNAs in cisplatin-resistant human non-small cell lung cancer cells (A549/DDP). *Exp. Lung Res*. 37: 427-434.

Whitman M. (1998). Smads and early developmental signaling by the TGFbeta superfamily. *Genes Dev*. 12: 2445-2462.

Winter J, Jung S, Keller S, Gregory RI, and Diederichs S. (2009). Many roads to maturity: microRNA biogenesis pathways and their regulation. *Nat. Cell Biol.* 11: 228-234.

Wölfel T, Hauer M, Schneider J, Serrano M, Wölfel C, Klehmann-Hieb E, De Plaen E, Hankeln T, Meyer zum Büschenfelde KH, and Beach D. (1995). A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. *Science.* 269: 1281-1284.

Wong E, and Giandomenico CM. (1999). Current status of platinum-based antitumor drugs. *Chem Rev.* 99:2451-2466.

WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre). Human Papillomavirus and Related Cancers in World. Summary Report 2010. [Accessed on October 10, 2011]. Available at <http://www.who.int/hpvcentre/en/>

Wyllie AH. (1980). Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. *Nature.* 284: 555-556.

Xia L, Zhang D, Du R, Pan Y, Zhao L, Sun S, Hong L, Liu J, and Fan D. (2008). miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. *Int. J. Cancer.* 123: 372-379.

Xia Z, Dickens M, Raingeaud J, Davis RJ, and Greenberg ME. (1995). Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. *Science.* 270: 1326-1331.

Yamamoto H, Monden T, Miyoshi H, Izawa H, Ikeda K, Tsujie M, Ohnishi T, Sekimoto M, Tomita N, and Monden M. (1998). Cdk2/cdc2 expression in colon carcinogenesis and effects of cdk2/cdc2 inhibitor in colon cancer cells. *Int. J. Oncol.* 13: 233-239.

Yang BH, Bray FI, Parkin DM, Sellors JW, and Zhang ZF. (2004). Cervical cancer as a priority for prevention in different world regions: an evaluation using years of life lost. *Int. J. Cancer.* 109: 418-424.

Yang C, Cai J, Wang Q, Tang H, Cao J, Wu L, and Wang Z. (2012). Epigenetic silencing of miR-130b in ovarian cancer promotes the development of multidrug resistance by targeting colony-stimulating factor 1. *Gynecol. Oncol.* 124:325-34.

Yang E, Zha J, Jockel J, Boise LH, Thompson CB, and Korsmeyer SJ. (1995). Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. *Cell.* 80: 285-291.

Yee C, Krishnan-Hewlett I, Baker CC, Schlegel R, and Howley PM. (1985). Presence and expression of human papillomavirus sequences in human cervical carcinoma cell lines. *Am. J. Path.* 119: 361-366.

Zainal AO, Zainuddin, MA, and Nor Saleha, IT. (2006). Malaysia Cancer Statistics - Data and Figure, Peninsular Malaysia. National Cancer Registry, Ministry of Health Malaysia.

Zeng Y, Forbes KC, Wu Z, Moreno S, Piwnica WH, and Enoch T. (1998). Replication checkpoint requires phosphorylation of the phosphatase Cdc25 by Cds1 or Chk1. *Nature*. 395: 507-510.

Zha J, Harada H, Yang E, Jockel J, and Korsmeyer SJ. (1996). Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). *Cell*. 87: 619-628.

Zhao L, Wientjes GM, and Au JLS. Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses. *Clin Cancer Res*. 2004; 10:7994–7904.

Zoli W, Ricotti L, Tesei A, Barzanti F, and Amadori D. (2001). *In vitro* preclinical models for a rational design of chemotherapy combinations in human tumors. *Crit. Rev. Oncol. Hematol*. 37: 69-82.

zur Hausen H, de Villiers EM, and Gissmann L. (1981). Papillomavirus infections and human genital cancers. *Gynecologic Oncology*. 12: 124-128